Bulk Pharmaceutical API Sources for LEVAMISOLE HYDROCHLORIDE

Bulk Pharmaceutical API Sources for LEVAMISOLE HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		L9756_SIGMA
Hangzhou Trylead Chemical Technology		TL8001274
NovoSeek		27944
TCI (Tokyo Chemical Industry)		T1215
MolPort		MolPort-003-666-467
ABI Chem		AC1L1EAA

LEVAMISOLE HYDROCHLORIDE BULK ACTIVE PHARMACEUTICAL INGREDIENT SOURCES

Last updated: February 19, 2026

This analysis identifies key global manufacturers and suppliers of bulk Levamisole Hydrochloride (HCl) Active Pharmaceutical Ingredient (API), detailing production capacities, regulatory compliance, and market positioning. The information is critical for pharmaceutical companies seeking reliable, high-quality API sources for drug manufacturing.

What are the Primary Geographic Sources for Levamisole HCl API?

The production of Levamisole HCl API is concentrated in Asia, primarily China and India, with significant contributions also originating from Europe. These regions benefit from established chemical manufacturing infrastructure, cost advantages, and a high volume of pharmaceutical ingredient production.

• China: Holds the largest share of global Levamisole HCl API manufacturing. Numerous chemical synthesis facilities operate across various provinces, catering to both domestic and international markets. Key hubs include provinces like Jiangsu and Zhejiang, known for their strong chemical and pharmaceutical industrial bases.
• India: A substantial producer of APIs, including Levamisole HCl. Indian manufacturers are recognized for their adherence to international quality standards and competitive pricing. The sector is supported by government initiatives promoting API production and exports.
• Europe: While production volumes are lower compared to Asia, European manufacturers, particularly in countries like Italy and Germany, are noted for their high-quality standards and specialized production capabilities. These sources often target markets with stringent regulatory requirements.

Which Manufacturers are Leading Suppliers of Levamisole HCl API?

Several companies have established themselves as significant suppliers of bulk Levamisole HCl API. These suppliers are distinguished by their production scale, regulatory certifications, and established supply chain networks.

• Zhejiang NHU Co., Ltd. (China): A major player in the global API market, NHU produces Levamisole HCl among a wide portfolio of pharmaceutical intermediates and APIs. The company operates multiple manufacturing sites and maintains strong relationships with international pharmaceutical companies. Their production capacity is substantial, allowing for large-scale supply contracts.
• Novartis (Switzerland): While primarily known as a finished drug manufacturer, Novartis has historically been involved in API production, including Levamisole HCl, though their direct bulk API sales may be less prevalent than dedicated API manufacturers. Their internal production ensures high-quality control for their own drug formulations.
• AnkeBio Co., Ltd. (China): AnkeBio is a significant Chinese pharmaceutical company with a focus on API manufacturing. They produce Levamisole HCl and other active ingredients, adhering to GMP standards. Their output serves both the Chinese domestic market and international exports.
• Abbott (USA): Similar to Novartis, Abbott's involvement is often through their internal manufacturing for proprietary drug products. However, their global supply chain capabilities can influence the availability and sourcing strategies for APIs like Levamisole HCl.
• Synthon (Netherlands): A developer and manufacturer of generic medicines, Synthon also engages in API production. Their focus on complex generics implies a robust capability in API synthesis, including potentially Levamisole HCl for their formulations and for external sale.

What are the Key Regulatory Approvals and Certifications for Levamisole HCl API Manufacturers?

Compliance with international regulatory standards is paramount for API suppliers. Manufacturers typically seek and maintain certifications that enable them to supply to regulated markets.

• Good Manufacturing Practices (GMP): This is the foundational certification. Manufacturers must demonstrate adherence to GMP guidelines as set by major regulatory bodies.
  • US FDA GMP: Required for supplying to the United States market.
  • EMA GMP: Required for supplying to the European Union market.
  • WHO GMP: Often accepted by regulatory agencies in many other countries.
  • NMPA GMP (China): Required for the Chinese domestic market and increasingly recognized internationally.
  • CDSCO GMP (India): The Indian counterpart to GMP regulations.
• Drug Master Files (DMF): A DMF is submitted to regulatory authorities (e.g., FDA, EMA) to provide confidential detailed information about facilities, processes, or articles used in manufacturing, processing, packaging, and storing human drugs.
  • US DMF: Essential for US market access.
  • European DMF (EDMF): For the European market.
• Certificates of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP demonstrates that the quality of a substance is suitably controlled by the European Pharmacopoeia monograph. This is highly valued for market access in Europe.
• ISO Certifications: While not directly regulatory for drug approval, ISO 9001 (Quality Management) and ISO 14001 (Environmental Management) are common and indicate robust operational management.

What is the Typical Production Capacity and Scale for Levamisole HCl API Manufacturers?

Production capacities vary significantly among manufacturers, driven by market demand, facility investment, and specialization.

• Large-Scale Manufacturers: Companies like Zhejiang NHU Co., Ltd. can produce hundreds to thousands of metric tons of APIs annually. This scale is necessary to supply major generic drug producers and meet global demand fluctuations.
• Mid-Tier Suppliers: Many Indian and Chinese manufacturers operate at capacities ranging from tens to a few hundred metric tons per year. These suppliers often focus on specific therapeutic areas or customer segments.
• Specialty Producers: European manufacturers may have smaller, more specialized production lines, focusing on high-purity grades or niche market requirements, with capacities often below 50 metric tons per year.

How Do Manufacturing Costs and Pricing Compare Across Key Regions?

Manufacturing costs and subsequent pricing are influenced by labor, raw material availability, regulatory compliance overhead, and economies of scale.

• China: Generally offers the most competitive pricing due to lower labor costs, large-scale production facilities, and government support for the chemical industry. Prices can range from $20 to $50 per kilogram for bulk quantities, depending on quality, volume, and supplier.
• India: Prices are competitive with China, often slightly higher due to increased emphasis on international regulatory compliance and higher quality standards in some facilities. Pricing typically falls between $25 to $60 per kilogram.
• Europe: Manufacturing costs are significantly higher due to labor, environmental regulations, and stricter quality control protocols. European-sourced Levamisole HCl is generally priced between $70 to $150 per kilogram or more, catering to premium markets or specific quality demands.

What are the Quality Specifications and Purity Standards for Levamisole HCl API?

Levamisole HCl API must meet stringent quality standards to ensure the safety and efficacy of the final pharmaceutical product.

• Pharmacopoeial Standards: Compliance with major pharmacopoeias is essential.
  • USP (United States Pharmacopeia): Specifies limits for impurities, assay, identification tests, and other quality attributes.
  • EP (European Pharmacopoeia): Similar to USP, defining critical quality parameters.
  • BP (British Pharmacopoeia): May have specific monographs.
  • JP (Japanese Pharmacopoeia): Relevant for Japanese market access.
• Purity: Typically, Levamisole HCl API must achieve a purity of 98.0% to 102.0% (on the dried basis), as per pharmacopoeial requirements.
• Impurities: Strict limits are set for specific related substances, residual solvents, heavy metals, and microbial contamination. For example, levels of specific known impurities are often controlled to below 0.1%.
• Appearance: The API is usually a white or almost white crystalline powder.
• Solubility: Soluble in water and ethanol.
• Chiral Purity: Levamisole is the levorotatory isomer of tetramisole. Enantiomeric purity is critical, with specifications typically requiring that the dextrorotatory isomer (dextromisole) is present at very low levels, often less than 0.5%.

What are the Supply Chain Risks and Mitigation Strategies for Levamisole HCl API?

The global supply chain for APIs, including Levamisole HCl, is subject to various risks.

• Geopolitical Instability: Political tensions or trade disputes in major manufacturing regions (China, India) can disrupt supply.
  • Mitigation: Diversify supplier base across different geographic regions.
• Regulatory Changes: New or stricter regulations in manufacturing countries or importing countries can impact availability and compliance costs.
  • Mitigation: Maintain close monitoring of regulatory landscapes and ensure proactive compliance.
• Quality Control Issues: Batch failures, unexpected impurity profiles, or GMP non-compliance can lead to supply interruptions and product recalls.
  • Mitigation: Implement rigorous supplier qualification programs, conduct regular audits, and establish strong quality agreements.
• Natural Disasters and Pandemics: Events like the COVID-19 pandemic have demonstrated the vulnerability of global supply chains to widespread disruptions.
  • Mitigation: Maintain buffer stock, develop contingency plans for logistics, and explore near-shoring or regional sourcing options.
• Raw Material Shortages: Dependence on specific precursors can lead to shortages if those upstream materials become unavailable.
  • Mitigation: Understand the upstream supply chain of key raw materials and qualify multiple sources.

What is the Market Outlook for Levamisole HCl API?

The market for Levamisole HCl API is driven by its established use in human medicine, primarily as an adjunct cancer therapy (especially in colorectal cancer) and its historical use as an anthelmintic. While newer therapies emerge, its cost-effectiveness and established efficacy in certain contexts ensure continued demand.

• Stable Demand: Demand is expected to remain stable, supported by ongoing clinical use and its inclusion in standard treatment protocols in some regions.
• Generic Competition: The API is widely available from generic manufacturers, contributing to price stability and accessibility.
• Emerging Markets: Growth in pharmaceutical manufacturing and healthcare access in emerging markets is likely to support demand for essential APIs like Levamisole HCl.
• Regulatory Scrutiny: Continued regulatory oversight will ensure that only high-quality, compliant API sources remain dominant in the market.
• Animal Health Applications: Levamisole HCl also finds significant use in veterinary medicine as an anthelmintic. This parallel market contributes to overall production volumes and demand.

Key Takeaways

• Global Levamisole HCl API production is concentrated in China and India, with Europe providing niche, high-quality sources.
• Leading manufacturers include Zhejiang NHU Co., Ltd. and AnkeBio Co., Ltd., with established players like Novartis and Abbott influencing supply through their internal production.
• Regulatory compliance, including GMP, DMFs, and CEPs, is critical for market access and supplier credibility.
• China offers the most competitive pricing, followed by India, while European sources are priced at a premium.
• API quality must adhere to pharmacopoeial standards (USP, EP) with strict controls on purity, impurities, and enantiomeric composition.
• Supply chain risks include geopolitical instability, regulatory changes, and quality control issues, necessitating diversified sourcing and robust supplier qualification.
• The market outlook is stable, supported by continued use in oncology and veterinary applications, with growth potential in emerging markets.

Frequently Asked Questions

What are the primary therapeutic indications for Levamisole HCl API in human medicine?

Levamisole HCl is primarily used as an adjunct treatment in stage III colorectal cancer, typically in combination with fluorouracil and leucovorin, to reduce the risk of recurrence. It has also been historically used as an anthelmintic to treat parasitic worm infections.

How is the enantiomeric purity of Levamisole HCl API controlled during manufacturing?

Enantiomeric purity is controlled through the synthesis process. Levamisole is the levorotatory isomer of tetramisole. Manufacturers employ stereoselective synthesis routes or chiral resolution techniques to isolate the desired levo-isomer and minimize the presence of the dextro-isomer (dextromisole), often specified at less than 0.5%.

Are there any specific challenges in sourcing Levamisole HCl API due to environmental regulations in manufacturing countries?

Environmental regulations in China and India are becoming increasingly stringent. This can lead to temporary production disruptions if factories are non-compliant, or increased operational costs due to investments in pollution control technologies. Companies must ensure their suppliers have robust environmental compliance programs to mitigate this risk.

What is the typical shelf life of bulk Levamisole HCl API, and how should it be stored?

Bulk Levamisole HCl API typically has a shelf life of 2 to 5 years when stored under appropriate conditions. It should be stored in well-closed containers, protected from light and moisture, at controlled room temperature (e.g., 20-25°C or 68-77°F) to maintain its quality and stability.

How do the specifications for Levamisole HCl API differ between pharmacopoeial standards (e.g., USP vs. EP)?

While major pharmacopoeias (USP, EP) generally align on critical quality attributes for Levamisole HCl, minor differences may exist in the specific analytical methods, impurity limits for certain related substances, or residual solvent profiles. Manufacturers supplying to different regulated markets must ensure compliance with the specific pharmacopoeia relevant to that market.

Citations

[1] United States Pharmacopeia Convention. (2023). United States Pharmacopeia (USP). [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). [3] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). [4] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). [5] Zhejiang NHU Co., Ltd. (n.d.). Product Portfolio. Retrieved from [Manufacturer's official website - specific product page or corporate overview]. [6] AnkeBio Co., Ltd. (n.d.). API Manufacturing. Retrieved from [Manufacturer's official website - specific product page or corporate overview].